This inventor holds 1 USPTO granted patent. Top assignee: Anhui University. Active years: 2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021
Title: Innovations of Liefeng Hu in Amphiphilic Polymer Prodrugs
Introduction
Liefeng Hu is a notable inventor based in Hefei, China. He has made significant contributions to the field of chemistry, particularly in the development of innovative drug delivery systems. His work focuses on creating advanced prodrugs that enhance therapeutic efficacy.
Latest Patents
Liefeng Hu holds a patent for a "Tetravalent platinum compound-bicyclic double-bond-containing amphiphilic polymer prodrug, nano-micelle, preparation method and application thereof." This invention involves a tetravalent platinum compound that is designed to improve drug delivery through a unique structure. The prodrug exhibits pH hypersensitivity and reduction dual responsiveness, making it a promising candidate for targeted therapy. The preparation method includes a reaction between an axially dihydroxy-coordinated tetravalent platinum compound and a bicyclic double-bond-containing orthoester precursor.
Career Highlights
Liefeng Hu is affiliated with Anhui University, where he continues to engage in research and development. His work has garnered attention for its potential applications in medical treatments, particularly in cancer therapy. With 1 patent to his name, he is recognized for his innovative approach to drug formulation.
Collaborations
Liefeng Hu collaborates with Rupei Tang, contributing to advancements in their shared field of research. Their partnership enhances the scope and impact of their work in developing new therapeutic strategies.
Conclusion
Liefeng Hu's contributions to the field of amphiphilic polymer prodrugs represent a significant advancement in drug delivery systems. His innovative research continues to pave the way for future developments in targeted therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile